136 related articles for article (PubMed ID: 32473104)
1. Treatment of Localized Cutaneous Leishmaniasis With Intralesional Meglumine Antimoniate and Photodynamic Therapy.
Costin A; Bonito F; Alves J; Barreiros H
Actas Dermosifiliogr (Engl Ed); 2020 Dec; 111(10):897-899. PubMed ID: 32473104
[No Abstract] [Full Text] [Related]
2. Successful treatment of cutaneous leishmaniasis with intralesional meglumine antimoniate: A case series.
Arboleda M; Barrantes S; Úsuga LY; Robledo SM
Rev Soc Bras Med Trop; 2019 May; 52():e20180211. PubMed ID: 31141044
[TBL] [Abstract][Full Text] [Related]
3. Standardization of intralesional meglumine antimoniate treatment for cutaneous leishmaniasis.
Duque MC; Vasconcellos ÉC; Pimentel MI; Lyra MR; Pacheco SJ; Marzochi MC; Rosalino CM; Schubach AO
Rev Soc Bras Med Trop; 2016; 49(6):774-776. PubMed ID: 28001228
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Intralesional Sodium Stibogluconate versus Intralesional Meglumine Antimoniate for the Treatment of Leishmania major Cutaneous Leishmaniasis.
Solomon M; Ollech A; Pavlotsky F; Barzilai A; Schwartz E; Baum S; Astman N
Acta Derm Venereol; 2024 Apr; 104():adv35089. PubMed ID: 38682801
[TBL] [Abstract][Full Text] [Related]
5. Intralesional treatment of cutaneous leishmaniasis with meglumine antimoniate.
Aste N; Pau M; Ferreli C; Biggio P
Br J Dermatol; 1998 Feb; 138(2):370-1. PubMed ID: 9602904
[No Abstract] [Full Text] [Related]
6. Weekly vs. fortnightly intralesional meglumine antimoniate in cutaneous leishmaniasis.
Mujtaba G; Khalid M
Int J Dermatol; 1999 Aug; 38(8):607-9. PubMed ID: 10487452
[No Abstract] [Full Text] [Related]
7. Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate.
Faghihi G; Tavakoli-kia R
Clin Exp Dermatol; 2003 Jan; 28(1):13-6. PubMed ID: 12558620
[TBL] [Abstract][Full Text] [Related]
8. Intralesional treatment with meglumine antimoniate in three patients with New World cutaneous leishmaniasis and large periarticular lesions with comorbidities.
Pimentel MIF; Vasconcellos ÉCFE; Ribeiro CO; Lyra MR; Saheki MN; Salgueiro MM; Antonio LF; Schubach AO
Rev Soc Bras Med Trop; 2017; 50(2):269-272. PubMed ID: 28562769
[TBL] [Abstract][Full Text] [Related]
9. Plasma antimony determination during cutaneous leishmaniasis treatment with intralesional infiltration of meglumine antimoniate.
de Aguiar MG; Gonçalves JE; Souza MD; de Silva RE; Silveira JN; Cota G
Trop Med Int Health; 2018 Oct; 23(10):1110-1117. PubMed ID: 30053341
[TBL] [Abstract][Full Text] [Related]
10. Resolution of cutaneous leishmaniasis after acute eczema due to intralesional meglumine antimoniate.
Ferreira e Vasconcellos Ede C; Pimentel MI; Valete-Rosalino CM; Madeira Mde F; Schubach Ade O
Rev Inst Med Trop Sao Paulo; 2014; 56(4):361-2. PubMed ID: 25076440
[TBL] [Abstract][Full Text] [Related]
11. Intralesional meglumine antimoniate for treatment of cutaneous leishmaniasis patients with contraindication to systemic therapy from Rio de Janeiro (2000 to 2006).
Vasconcellos Ede C; Pimentel MI; Schubach Ade O; de Oliveira Rde V; Azeredo-Coutinho RB; Silva Fda C; Salgueiro Mde M; Moreira JS; Madeira Mde F; Baptista C; Valete-Rosalino CM
Am J Trop Med Hyg; 2012 Aug; 87(2):257-60. PubMed ID: 22855754
[TBL] [Abstract][Full Text] [Related]
12. [Antimonial treatments of leishmaniasis].
Oliveira Neto MP
Rev Soc Bras Med Trop; 2005; 38(5):446. PubMed ID: 16172767
[No Abstract] [Full Text] [Related]
13. Treatment of Old World cutaneous leishmaniasis with intralesionally injected meglumine antimoniate using a Dermojet device.
Bogenrieder T; Lehn N; Landthaler M; Stolz W
Dermatology; 2003; 206(3):269-72. PubMed ID: 12673089
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of treatment with intralesional meglumine antimoniate alone, compared with that of cryotherapy combined with the meglumine antimoniate or intralesional sodium stibogluconate, in the treatment of cutaneous leishmaniasis.
Asilian A; Sadeghinia A; Faghihi G; Momeni A; Amini Harandi A
Ann Trop Med Parasitol; 2003 Jul; 97(5):493-8. PubMed ID: 12930612
[TBL] [Abstract][Full Text] [Related]
15. Comparison between systemic and intralesional meglumine antimoniate therapy in a primary health care unit.
de Oliveira Duque MC; Quintão Silva JJ; Soares PAO; Magalhães RS; Horta APA; Paes LRB; Rosandiski Lyra M; Pimentel MIF; de Fátima Antonio L; de Camargo Ferreira E Vasconcellos É; Saheki MN; de Almeida Marzochi MC; Valete-Rosalino CM; de Oliveira Schubach A
Acta Trop; 2019 May; 193():176-182. PubMed ID: 30851256
[TBL] [Abstract][Full Text] [Related]
16. Intralesional infiltration versus parenteral use of meglumine antimoniate for treatment of cutaneous leishmaniasis: A cost-effectiveness analysis.
Brito NC; Machado de Assis TS; Rabello A; Cota G
PLoS Negl Trop Dis; 2019 Dec; 13(12):e0007856. PubMed ID: 31805052
[TBL] [Abstract][Full Text] [Related]
17. Safety profile of meglumine antimoniate intralesional infiltration for cutaneous leishmaniasis.
Fernandes HJ; da Silva RE; Ramalho DB; Aguiar MG; Silveira JN; Cota G
Expert Rev Anti Infect Ther; 2020 Apr; 18(4):381-387. PubMed ID: 32067521
[No Abstract] [Full Text] [Related]
18. The activity of encapsulated meglumine antimoniate in stearylamine-bearing liposomes against cutaneous leishmaniasis in BALB/c mice.
Moosavian SA; Fallah M; Jaafari MR
Exp Parasitol; 2019 May; 200():30-35. PubMed ID: 30898544
[TBL] [Abstract][Full Text] [Related]
19. A double-blind randomized clinical trial of a topical herbal extract (Z-HE) vs. systemic meglumine antimoniate for the treatment of cutaneous leishmaniasis in Iran.
Zerehsaz F; Salmanpour R; Handjani F; Ardehali S; Panjehshahin MR; Tabei SZ; Tabatabaee HR
Int J Dermatol; 1999 Aug; 38(8):610-2. PubMed ID: 10487453
[No Abstract] [Full Text] [Related]
20. Localized leishmaniasis treated with intralesional meglumine antimoniate.
Villela-Segura U; Proy-Trujillo H; Ilizaliturri-Flores I; Leal-Ascencio VJ; Eljure-López N
J Dtsch Dermatol Ges; 2020 Sep; 18(9):1025-1027. PubMed ID: 32656933
[No Abstract] [Full Text] [Related]
[Next] [New Search]
